Induction of apoptosis in neuroendocrine tumors of the digestive system during treatment with somatostatin analogs

Acta Oncologica

Volumn 36, Issue 6, 1997, Pages 607-614

  Imam, Hassan ^a   Eriksson, Barbro ^a   Lukinius, Agneta ^a   Janson, Eva T ^a   Lindgren, Per Gunnar ^a   Wilander, Erik ^a   Öberg, Kjell ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; OCTREOTIDE; PLACEBO; RECOMBINANT ALPHA2B INTERFERON; SOMATOSTATIN DERIVATIVE;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE; CELL DEATH; COMPUTER ASSISTED TOMOGRAPHY; DIGESTIVE SYSTEM CANCER; DNA NICK TRANSLATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; MOUSE; NEUROENDOCRINE TUMOR; NONHUMAN; PRIORITY JOURNAL; TREATMENT OUTCOME; TUMOR GROWTH; ZOLLINGER ELLISON SYNDROME;

EID: 0030856194     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.3109/02841869709001323     Document Type: Article

References (30)

1. Wilander E, Lundqvist M, Oberg K. Gastrointestinal carcinoid tumours. Histogenetic, histochemical, immunohistochemical, clinical and therapeutic aspects. Prog Histochem Cytochem 1989; 19: 1 88.
2. Welbourn RB. Apudomas of the gut. Am J Surg 1977; 133: 13-22.
3. Moertel CG. Treatment of carcinoid tumor and malignant carcinoid syndrom. J Clin Oncol. 1983; 1: 727 40.
4. Kvols LK, Buck M. Chemotherapy of metastatic carcinoid and islet cell tumors. A review. Am J Med 1987; 82: 77 83.
5. Öberg K, Eriksson B, Medical treatment of neuroendocrine gut and pancreatic tumors. Acta Oncol 1989; 28: 425 31.
6. Öberg K, Funa K, Alm G. Effects of leukocyte interferon on clinical symptoms and hormone levels in patients with midgut carcinoid tumors and carcinoid syndrome. N Engl J Med 1983: 309: 129 33.
7. Tiensuu Janson EM, Ahlstrom H, Andersson T, Öberg KE. Octreotide and interferon alfa: a new combination for the treatment of malignant carcinoid tumours. Eur J Cancer 1992: 28A: 1647 50.
8. Kerr JFR, Wyllie AH, Currie AR, Apoptosis: a basic biological phenomenon with wide ranging implications in tissue kinetics. Brit J Cancer 1972; 26: 239 57.
9. Wyllie All, Kerr JF, Currie AR. Cell death: the significance of apoptosis. Int Rev Cytol 1980; 68: 251 306.
10. Korsmeyer SJ. Programmed cell death: Bcl-2. In: DeVita Jr VT. Hellman S, Rosenberg SA. Important advances in oncology. Philadelphia: JB Lippincott Company, 1993; 19 28.
11. Hickman JA. Apoptosis induced by anticancer drugs. Cancer Metastasis Rev 1992; 11: 121 39.
12. Evers BM, Ishizuka J, Townsend CMJ, Thompson JC. The human carcinoid cell line, BON. A model system for the study of carcinoid tumors. Ann N Y Acad Sci 1994; 733: 393 406.
13. Gavrieli Y, Sherman Y, Ben-Sasson SA. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 1992: 119: 493 501.
14. Smith RE, Farquhar MG. Lysosome function in the regulation of the secretory process in cells of the anterior pituitary gland. J Cell Biol. 1966; 31: 319 47.
15. Andersson T, Wilander E, Eriksson B, Lindgren PG, Oberg K. Effects of interferon on tumor tissue content in liver metastases of human carcinoid tumors. Cancer Res 1990; 50: 3413 5.
16. Szende B, Schally AV, Comaru-Schally AM, et al. Cellular and molecular aspects of apoptosis in experimental tumors of animals treated with analogs of LHRH, somatostatin. In: David Tomei L, Frederick OC. Apoptosis: The molecular basis of cell death. New York: Cold Spring Harbor Laboratory Press, 1991; 139 55.
17. Reubi JC, Schaer JC, Waser B. Mengod G. Expression and localization of somatostatin receptor SSTR1, SSTR2, and SSTR3 messenger RNAs in primary human tumors using in situ hybridization. Cancer Res 1994: 54: 3455 9.
18. Kubota A, Yamada Y, Kagimoto S. et al. Identification of somatostatin receptor subtypes and an implication for the efficacy of somatostatin analogue SMS 201 995 in treatment of human endocrine tumors. J Clin Invest 1994; 93: 1321 5.
19. Buscail L, Esteve JP, Saint-Laurent N, et al. Inhibition of cell proliferation by the somatostatin analogue RC-160 is mediated by somatostatin receptor subtypes SSTR2 and SSTR5 through different mechanisms. Proc Natl Acad Sci USA 1995: 92: 1580 4.
20. Lamberts SW, van der Lely AJ, de Herder WW, Holland LJ, Octreotide. N Engl J Med (UNITED STATES) 1996; 334: 246 54.
21. Evers BM, Hurlbut SC, Tyring SK, Townsend CMJ, Uchida T, Thompson JC. Novel therapy for the treatment of human carcinoid. Ann Surg 1991; 213: 411 6.
22. Bursch W, Kleine L, Tenniswood M. The biochemistry of cell death by apoptosis. Biochem Cell Biol 1990; 68: 1071 4.
23. Tormanen U, Eerola AK, Rainio P, et al. Enhanced apoptosis predicts shortened survival in non-small cell lung carcinoma. Cancer Res 1995; 55: 5595 602.
24. Lipponen PK, Aaltomaa S. Apoptosis in bladder cancer as related to standard prognostic factors and prognosis. J Pathol 1994; 173: 333 9.
25. Tatebe S, Ishida M, Kasagi N, Tsujitani S, Kaibara N, Ito H. Apoptosis occurs more frequently in metastatic foci than in primary lesions of human coloreclal carcinomas: analysis by terminal-deoxynucleotidyl-transferase-mediated dUTP-biotin nick end labeling. Int J Cancer 1996; 65: 173 7.
26. Lowe SW, Schmitt EM, Smith SW, Osborne BA, Jacks T. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 1993: 362: 847 9.
27. Creasey AA, Bartholomew JC, Merigan TC. Role of G0-G1 arrest in the inhibition of tumor cell growth by Interferon. Proc Natl Acad Sci USA 1980; 77: 1471 5.
28. Panayiotidis P, Ganeshaguru K, Jabbar SA, Hoffbrand AV. Alpha-interferon (alpha-IFN) protects B-chronic lymphocytic leukaemia cells from apoptotic cell death in vitro. Br J Haematol 1994; 86: 169 73.
29. Vedantham S, Gamliel H, Golomb HM. Mechanism of interferon action in hairy cell leukemia: a model of effective cancer biotherapy. Cancer Res 1992; 52: 1056 66.
30. Ezekowitz RA, Mulliken JB, Folkman J. Interferon alfa-2a therapy for life-threatening hemangiomas of infancy. N Engl J Med 1992; 326: 1456 63.